期刊
CURRENT OPINION IN RHEUMATOLOGY
卷 28, 期 2, 页码 168-175出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BOR.0000000000000250
关键词
biomarker development; biomarkers; mechanistic biomarkers; precision medicine; rheumatic diseases
类别
资金
- Department of Veteran Affairs
- NIH NHLBI Proteomics Center [N01-HV 00242]
- NIH NIAMS [R01 AR063676]
- NIH NIAID [U01 AI101981, U01 AI057229, U19 AI110491]
- NIH NCI [R33 CA183659]
- NIH NIAMS/NIAID/FNIH AMP Program [UH2 AR067681]
- Brennan Family
- Northern California Chapter of the Arthritis Foundation (NCCAF) Center of Excellence
- Bill and Melinda Gates Foundation
Purpose of reviewThe use of biomarkers in rheumatology can help identify disease risk, improve diagnosis and prognosis, target therapy, assess response to treatment, and further our understanding of the underlying pathogenesis of disease. Here, we discuss the recent advances in biomarkers for rheumatic disorders, existing impediments to progress in this field, and the potential of biomarkers to enable precision medicine and thereby transform rheumatology.Recent findingsAlthough significant challenges remain, progress continues to be made in biomarker discovery and development for rheumatic diseases. The use of next-generation technologies, including large-scale sequencing, proteomic technologies, metabolomic technologies, mass cytometry, and other single-cell analysis and multianalyte analysis technologies, has yielded a slew of new candidate biomarkers. Nevertheless, these biomarkers still require rigorous validation and have yet to make their way into clinical practice and therapeutic development. This review focuses on advances in the biomarker field in the last 12 months as well as the challenges that remain.SummaryBetter biomarkers, ideally mechanistic ones, are needed to guide clinical decision making in rheumatology. Although the use of next-generation techniques for biomarker discovery is making headway, it is imperative that the roadblocks in our search for new biomarkers are overcome to enable identification of biomarkers with greater diagnostic and predictive utility. Identification of biomarkers with robust diagnostic and predictive utility would enable precision medicine in rheumatology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据